IFOM Elisabetta Dejana Lab

Elisabetta Dejana Lab

Elisabetta Dejana

Elisabetta Dejana, a cell biologist and expert on regulation of vascular system development, directs the New strategies to inhibit tumor angiogenesis research unit at IFOM, which focuses on development of tumor vasculature.
After earning a degree in Biological Sciences from the University of Bologna, she moved to Milan to work at the Mario Negri Institute for Pharmacological Research, where she investigated the mechanisms underlying pathological thrombosis and cardiovascular diseases. read more

Contact the researcher

New strategies to inhibit tumor angiogenesis

One of the innovative aspects of anti-cancer therapies concerns the possibility of inhibiting tumor growth by blocking blood supply. The simple idea is that, if starved, the tumor will not grow but, on the contrary, will shrink and become more susceptible to chemotherapy and radiotherapy. Cancer cells induce the formation of their own vascular system by recruiting new vessels from the host. However, the resulting vasculature is structurally and functionally abnormal. read more

Laboratory location: Milan, Italy

Recent publications

Group members - IFOM

Technician
Corada Monica
Maderna Claudio
Orsenigo Fabrizio
Guest Researcher
Lampugnani Maria Grazia
Post Doc
Giannotta Monica
Kakogiannos Nikolaos
Lazzaroni Francesca
Post Doc - Guest
Malinverno Matteo
PhD Student
Scalise Anna Agata
Valentino Mariaelena
Former lab members
Stefan Liebner (Group Leader at Institute of Neurology, Johann Wolfgang Goethe-University Frankfurt, Germany)
Luigi Maddaluno (ETH, Zurich, Switzerland)
Daniel Nyqvist (Group Leader at Karolinska Insitutet, Stockholm, Sweden)
Andrea Taddei (Cancer Research UK, London)

(update: Mar 2021)

Group members - Uppsala Universitet

Lab Members

IFOM Review

Drug repositioning - A rapid and economic alternative to 'traditional' drug development
The case of cavernomas and an old chemotherapeutic that the industry was phasing out of production. (2014)
Cell therapy for muscular dystrophy: a step towards efficacy.
Commentary on Elisabetta Dejana's paper published on EMBO Molecular Medicine, by Giulio Cossu (2014)
Arterial fate decision revised: Sox17 links Wnt/β-catenin and Notch signaling
Commentary on Elisabetta Dejana's paper published on Nature Communications, by Stefan Liebner (2013)
The role of VE-cadherin in vascular permeability
Commentary on Elisabetta Dejana's paper published on Nature Communications, by Michael A. Gimbrone Jr. (2012)
complete review

In the press

Vivisezione, l'Europa non la ferma e riparte il dibattito
2015-05-06

Il Corriere della Sera | Giovanni Caprara

Alle ricerche sui cavernomi il premio Feltrinelli
Corriere della Sera

2014.11.19 | Giovanni Caprara

Le frontiere del biotech spiegate agli studenti
Il Giornale

2014.10.09

Biotech 4 Young, il futuro della biotecnologia è qui
Glamour

2014.10.09

Biotech 4 Young, Wired e Farmindustria per i giovani
GQ

2014.10.08

view all press review

Media